JPWO2022130014A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022130014A5 JPWO2022130014A5 JP2023536584A JP2023536584A JPWO2022130014A5 JP WO2022130014 A5 JPWO2022130014 A5 JP WO2022130014A5 JP 2023536584 A JP2023536584 A JP 2023536584A JP 2023536584 A JP2023536584 A JP 2023536584A JP WO2022130014 A5 JPWO2022130014 A5 JP WO2022130014A5
- Authority
- JP
- Japan
- Prior art keywords
- raav vector
- vector
- promoter
- plasma kallikrein
- raav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126300P | 2020-12-16 | 2020-12-16 | |
| US63/126,300 | 2020-12-16 | ||
| PCT/IB2021/000874 WO2022130014A1 (en) | 2020-12-16 | 2021-12-15 | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023554066A JP2023554066A (ja) | 2023-12-26 |
| JPWO2022130014A5 true JPWO2022130014A5 (https=) | 2024-12-23 |
| JP2023554066A5 JP2023554066A5 (https=) | 2024-12-23 |
Family
ID=80461568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536584A Pending JP2023554066A (ja) | 2020-12-16 | 2021-12-15 | 血漿カリクレインの制御不全によって媒介される疾患の処置のための抗体のアデノ随伴ウイルスベクター送達 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220186252A1 (https=) |
| EP (1) | EP4263614A1 (https=) |
| JP (1) | JP2023554066A (https=) |
| CN (1) | CN116829595A (https=) |
| WO (1) | WO2022130014A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116790615B (zh) * | 2023-07-11 | 2024-11-22 | 康霖生物科技（杭州）有限公司 | 一种用于过敏性疾病的基因治疗载体核酸构建体及其使用方法 |
| GB202402816D0 (en) * | 2024-02-28 | 2024-04-10 | Imperial College Innovations Ltd | Self-amplifying RNA molecule |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
| US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| EP1438075A4 (en) | 2001-10-02 | 2006-04-19 | Inst Clayton De La Rech | METHOD AND COMPOSITIONS ASSOCIATED WITH LENTIVIRAL VECTORS WITH LIMITED EXPRESSION AND ITS APPLICATIONS |
| US7816131B2 (en) | 2004-04-02 | 2010-10-19 | Board Of Regents, The University Of Texas System | Cancer specific promoters |
| US8865881B2 (en) | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
| GB201206455D0 (en) | 2012-04-12 | 2012-05-30 | Royal Holloway & Bedford New College | Gene expression |
| WO2014152232A2 (en) | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| JP2016517440A (ja) | 2013-03-15 | 2016-06-16 | ブイエルピー バイオテック，インコーポレイテッド | パリビズマブエピトープベースのウイルス様粒子 |
| CN107249646B (zh) | 2014-12-16 | 2021-06-29 | 内布拉斯加大学董事会 | 用于青少年巴滕病的基因疗法 |
| CL2014003590A1 (es) | 2014-12-30 | 2015-07-10 | Univ Chile | Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimizacion y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje. |
| MA41346A (fr) | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
| US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
| GB2547179A (en) | 2015-10-26 | 2017-08-16 | Quethera Ltd | Genetic construct |
| CN108291238A (zh) | 2015-10-27 | 2018-07-17 | 赛尔希恩公司 | 嵌合转录后调控元件 |
| CN109415687A (zh) | 2016-04-07 | 2019-03-01 | 蓝鸟生物公司 | 嵌合抗原受体t细胞组合物 |
| JP7632835B2 (ja) | 2016-05-20 | 2025-02-19 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 加齢関連疾患及び症状の遺伝子治療法 |
| CN110662839A (zh) | 2017-02-17 | 2020-01-07 | 珀杜研究基金会 | 用于细胞疗法的基于靶向性配体-有效负载的药物递送 |
| KR20220012231A (ko) * | 2019-04-24 | 2022-02-03 | 리젠엑스바이오 인크. | 완전-인간 번역 후 변형된 항체 치료제 |
| EP4048800A1 (en) * | 2019-10-23 | 2022-08-31 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
| US20230390418A1 (en) * | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
-
2021
- 2021-12-15 US US17/552,174 patent/US20220186252A1/en not_active Abandoned
- 2021-12-15 EP EP21863063.0A patent/EP4263614A1/en active Pending
- 2021-12-15 CN CN202180093553.4A patent/CN116829595A/zh active Pending
- 2021-12-15 JP JP2023536584A patent/JP2023554066A/ja active Pending
- 2021-12-15 WO PCT/IB2021/000874 patent/WO2022130014A1/en not_active Ceased